KR900700153A - 생리학적 활성물질 투여를 위한 폐색체 - Google Patents
생리학적 활성물질 투여를 위한 폐색체Info
- Publication number
- KR900700153A KR900700153A KR1019890701941A KR890701941A KR900700153A KR 900700153 A KR900700153 A KR 900700153A KR 1019890701941 A KR1019890701941 A KR 1019890701941A KR 890701941 A KR890701941 A KR 890701941A KR 900700153 A KR900700153 A KR 900700153A
- Authority
- KR
- South Korea
- Prior art keywords
- reservoir
- obturator
- active substance
- physiologically active
- membrane
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims 12
- 239000012528 membrane Substances 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 4
- 239000000853 adhesive Substances 0.000 claims 3
- 230000001070 adhesive effect Effects 0.000 claims 3
- -1 ephedran Chemical compound 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 239000012982 microporous membrane Substances 0.000 claims 3
- 229940111630 tea tree oil Drugs 0.000 claims 3
- 239000010677 tea tree oil Substances 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (16)
- 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체에 잇어서, 상기 폐색체는 액체 형태의 생리학적 활성물질을 포함하는 저장소, 생리학적 활성 물질이 통과할수 있고 활성물질과 가까이 있는 미소다공질 막으로 구성된 저장소 벽, 및 저장소내의 점성의 유동겔에 의해 실제로 고정된 액체 내용물로 구성하되 a)상기 막(3)은 소수성이고, 상기 저장소는 친수성 습윤제를 포함하거나, b)상기 막(3)은 친수성이고 상기 저장소 내용물은 소수성인 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체.
- 제1항에 있어서, 막(3)이 접착제(2)로 코팅된것을 특징으로 하는 폐색체.
- 제2항에 있어서, 접착제는 실리콘에 기초를 둔 접착제임을 특징으로 하는 폐색체.
- 상기 청구항중 어느 한 항에 있어서, 막(3)이 소수성이고 상기 저장소가 친수성 습윤제를 포함하는 것을 특징으로 하는 폐색체.
- 제4항에 있어서, 저장소 내용물은 점성도 저절제나 계면활성제 역활도 하는 가소제와 함께 무롤 구성되는 것을 특징으로 하는 폐색체.
- 제5항에 있어서, 계면 활성제는 메틸 셀룰로오즈로 구성되는 것을 특징으로 하는 폐색체.
- 제6항에 있어서, 메틸 셀룰로오즈의 양이 저장소 내용물에 관하여 무게당 약 5% 내지 6%인 것을 특징으로 하는 폐색체.
- 상기 청구항 중 어느 한 항에 있어서, 생리학적 활성물질이 니코틴인 것을 특징으로 하는 폐색체.
- 제8항에 있어서, 니코틴의 양이 저장소의 전체 액체 내용물의 무게당 2% 내지 10%인 것을 특징으로 하는 폐색체.
- 상기 청구항 중 어느 한 항에 있어서, 저장소 내용물이 차나무 기름을 포함하는 것을 특징으로 하는 폐색체.
- 제10항에 잇어서, 차나무 기름의 양이 저장소의 액체 내용물의 무게당 0.05%내지 2%인 것을 특징으로 하는 폐색체.
- 제1항 내지 7항 중 어느 한 항에 있어서, 생리학적 활성 물질이 파라세타몰, 에페드란, 펜타닐, 티몰올, 클로니딘, 히오스친, 에스트라디올, 프로게스테론, 살부타몰, 또는 테스토스테론인 것을 특징으로 하는 폐색체.
- 상기 청구항 중 어느 한 항에 있어서, 저장소가 금속 또는 플라스틱 엷은 판으로 된 불침투성 뒷받침(4)로 구성되는 것을 특징으로 하는 폐색체.
- 상기 청구항 중 어느 한 항에 있어서, 상기 생리학적 활성 물질이 저장소 내용물의 무게당 25%이상을 차지하지 않기 위하여 적어도 하나의 희석제와 함께 존재하는 것을 특징으로 하는 폐색체.
- 상기 청구항 중 어느 한 항에 있어서, 상기 저장소의 벽이 미소다공질 막의 외부 표면과 가까이 있는 침투성 막으로 구성되어 있고, 상시 침투성 막이 상기 미소다공질 막(3)의 습윤력과 같거나 다른 습윤력을 가지는 것을 특징으로 하는 폐색체.
- 폐색체가 액체 형태의 활성 물질을 포함하는 저장소, 활성 물질이 침투할수 있는 저장소 벽(3) 및, 차나무 기름이나 그의 주요성분을 부가적으로 포함하는 저장소로 구성된 것을 특징으로 하는 생리학적 활성 물질을 피부로 통해 투여하기 위한 폐색체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8804164 | 1988-02-23 | ||
GB888804164A GB8804164D0 (en) | 1988-02-23 | 1988-02-23 | Bandage for administering physiologically active compound |
GB?88-04164? | 1988-02-23 | ||
PCT/GB1989/000185 WO1989007959A1 (en) | 1988-02-23 | 1989-02-23 | Occlusive body for administering a physiologically active substance |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900700153A true KR900700153A (ko) | 1990-08-11 |
KR970009723B1 KR970009723B1 (ko) | 1997-06-17 |
Family
ID=10632193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890701941A KR970009723B1 (ko) | 1988-02-23 | 1989-02-23 | 생리학적 활성물질의 경피성 투여용 폐색체 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5254346A (ko) |
EP (2) | EP0508979B1 (ko) |
JP (1) | JP2716231B2 (ko) |
KR (1) | KR970009723B1 (ko) |
AU (1) | AU618085B2 (ko) |
DE (1) | DE68915291T2 (ko) |
ES (1) | ES2052071T3 (ko) |
GB (1) | GB8804164D0 (ko) |
IN (1) | IN172748B (ko) |
WO (1) | WO1989007959A1 (ko) |
ZA (1) | ZA891403B (ko) |
Families Citing this family (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
JPH02149514A (ja) * | 1988-04-06 | 1990-06-08 | Nitto Denko Corp | 医薬部材 |
DE69108136T2 (de) * | 1990-08-03 | 1995-11-02 | Terumo Corp | Wundabdeckmaterial. |
GB9021674D0 (en) * | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
US5240917A (en) * | 1991-04-03 | 1993-08-31 | Keimowitz Rudolph M | Suppression of thromboxane levels by percutaneous administration of aspirin |
US5123900A (en) * | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
CH686816A5 (de) * | 1992-02-04 | 1996-07-15 | Asulab Ag | Einrichtung zur Abgabe eines Arzneimittels. |
US6071896A (en) * | 1992-06-16 | 2000-06-06 | Gundersen Clinic, Ltd. | Suppression of thromboxane levels by percutaneous administration of aspirin |
DE9219105U1 (de) * | 1992-10-31 | 1998-03-05 | Klocke Verpackungs-Service GmbH, 76356 Weingarten | Behälter zur Aufnahme von aromatischen Substanzen |
JPH08503465A (ja) * | 1992-11-09 | 1996-04-16 | ファーメトリックス コーポレイション | ケトロラックの経皮デリバリー |
FR2709670B1 (fr) * | 1993-09-10 | 1995-10-20 | Asulab Sa | Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse. |
WO1995024172A1 (en) * | 1994-03-07 | 1995-09-14 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
DE4423850A1 (de) * | 1994-07-07 | 1996-01-11 | Labtec Gmbh | Transdermales therapeutisches System zur Applikation von Naloxon |
DE19517145C2 (de) * | 1995-05-10 | 2000-02-24 | Hexal Pharmaforschung Gmbh | Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron |
US5730721A (en) | 1996-01-25 | 1998-03-24 | Vesture Corporation | Medical applicator and method |
US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US6119036A (en) | 1997-03-26 | 2000-09-12 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
US5919476A (en) * | 1997-09-29 | 1999-07-06 | Pmt Corporation | Reinforced gel sheeting for scar treatment |
DE19743484C1 (de) * | 1997-10-01 | 1999-01-28 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems |
US7011843B2 (en) | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
WO1999061007A1 (de) * | 1998-05-22 | 1999-12-02 | Novosis Pharma Ag | Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme |
DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
DE19934523A1 (de) * | 1999-07-22 | 2001-01-25 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich |
US7713546B1 (en) | 2001-04-03 | 2010-05-11 | Soft Gel Technologies, Inc. | Corosolic acid formulation and its application for weight-loss management and blood sugar balance |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
RU2276998C2 (ru) | 2001-05-01 | 2006-05-27 | Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук | Гидрогелевые композиции |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
AU2002316053A1 (en) | 2001-05-01 | 2002-11-11 | A.V. Topchiev Institute Of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2492654A1 (en) * | 2002-07-16 | 2004-01-22 | University Of South Florida | Human immunosuppressive protein |
EP2130541A3 (en) | 2002-07-29 | 2013-12-18 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP2006510618A (ja) | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス,インコーポレーテッド | ノルケタミンおよびケタミン/ノルケタミンプロドラッグの鎮痛的使用 |
CA2453013C (en) * | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
WO2004093788A2 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
CA2530996C (en) | 2003-07-03 | 2013-05-07 | Corium International, Inc. | Wound dressing, ingredient delivery device and iv hold-down, and method relating to same |
WO2005013996A2 (en) | 2003-08-07 | 2005-02-17 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
EP1663168B1 (en) * | 2003-09-08 | 2009-02-11 | McNeil AB | Nicotine formulations and use thereof |
EP1713450B1 (en) | 2004-01-30 | 2021-10-06 | Corium, Inc. | Rapidly dissolving film for delivery of an active agent |
US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
AU2005238034A1 (en) * | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
US20050249791A1 (en) * | 2004-05-07 | 2005-11-10 | 3M Innovative Properties Company | Antimicrobial articles |
GB2414461B (en) * | 2004-05-24 | 2007-09-12 | Mark Rupert Tucker | Form-fill-seal process |
MX2007001512A (es) | 2004-08-05 | 2007-04-20 | Corium Int Inc | Composicion adhesiva. |
US20060051435A1 (en) * | 2004-08-19 | 2006-03-09 | Udell Ronald G | Nutritional supplement for body fat reduction |
US20060079514A1 (en) * | 2004-10-13 | 2006-04-13 | Victory Pharma Incorporated | Methods and compositions including methscopolamine bromide |
US20060079513A1 (en) * | 2004-10-13 | 2006-04-13 | Preston David M | Methods and compositions including methscopolamine nitrate |
US8252320B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
ATE551995T1 (de) | 2004-10-21 | 2012-04-15 | Durect Corp | Transdermale abgabesysteme |
GB2421431B (en) * | 2004-12-24 | 2007-10-10 | Aquasol Ltd | Dosing systems |
US20070104805A1 (en) * | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
AT502717A1 (de) * | 2005-11-09 | 2007-05-15 | Omnica Gmbh | Pharmazeutische verwendung einer verbindung |
GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
EP1965776A1 (en) * | 2005-12-08 | 2008-09-10 | Fertin Pharma | Low flexural strength transdermal tobacco alkaloid patch |
EP1965777A1 (en) * | 2005-12-08 | 2008-09-10 | Fertin Pharma | Transdermal tobacco alkaloid patch |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US9109204B2 (en) * | 2006-02-28 | 2015-08-18 | The Trustees Of Columbia University In The City Of New York | Methods for compact aggregation of dermal cells |
AT503329A1 (de) * | 2006-03-02 | 2007-09-15 | Omnica Gmbh | Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält |
AT503521A1 (de) * | 2006-05-05 | 2007-11-15 | Omnica Gmbh | Verwendung eines extraktes von kiwi-frucht |
US8278358B2 (en) * | 2006-07-06 | 2012-10-02 | Omnica Gmbh | Lipoic acid derivatives |
NZ574361A (en) | 2006-07-21 | 2012-02-24 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with enhanced uptake containing buprenorphine |
JP2008044926A (ja) * | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
DE602007012363D1 (de) | 2006-10-19 | 2011-03-17 | Rigel Pharmaceuticals Inc | 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen |
ES2380551T3 (es) | 2006-11-21 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos |
US7820207B2 (en) * | 2007-03-15 | 2010-10-26 | Omnica Gmbh | Stabilized anthocyanin compositions |
US8623429B2 (en) | 2007-03-15 | 2014-01-07 | Omnica Gmbh | Stabilized anthocyanin compositions |
US20080293644A1 (en) * | 2007-04-27 | 2008-11-27 | Thomas Eidenberger | Guava extract |
AU2007353989A1 (en) * | 2007-05-31 | 2008-12-04 | Fertin Pharma A/S | Transdermal tobacco alkaloid reservoir patch |
WO2009027850A2 (en) * | 2007-06-06 | 2009-03-05 | Multi-Tech Specialty Chemicals Co., Ltd. | Process for the preparation of xanthophyll crystals |
DK2176208T3 (en) * | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2009089380A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of Columbia University In The City Of New York | Methods for p2ry5 mediated regulation of hair growth and mutants thereof |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
CN103508936A (zh) | 2008-08-22 | 2014-01-15 | 赛诺菲-安万特 | 用于制备吲哚苄胺化合物的中间体 |
JP2012503005A (ja) * | 2008-09-19 | 2012-02-02 | インスティテュート フォア ワンワールド ヘルス | イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。 |
TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
ES2624622T3 (es) | 2008-12-30 | 2017-07-17 | Rigel Pharmaceuticals, Inc. | Inhibidores de pirimidindiamina cinasa |
AU2010204986B2 (en) | 2009-01-14 | 2016-06-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP3620154A1 (en) | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
BR112012000254A2 (pt) | 2009-07-08 | 2016-02-16 | Dermira Canada Inc | análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas. |
US20110034415A1 (en) * | 2009-07-20 | 2011-02-10 | Thomas Eidenberger | Walnut extracts for nutraceutical applications |
WO2011022371A2 (en) * | 2009-08-17 | 2011-02-24 | Silipos Inc. | Gel product |
FR2955324A1 (fr) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
US20110144200A1 (en) | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
CA2785439A1 (en) | 2009-12-23 | 2011-06-30 | Sanofi | [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
PL2516418T3 (pl) | 2009-12-23 | 2014-10-31 | Sanofi Sa | Proleki [4-[4-(5-aminometylo-2-fluoro-fenylo)-piperydyn-1-ylo]-(1H-pirolo-pirydynylo)-metanonów oraz ich synteza |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
US20110288103A1 (en) | 2010-04-20 | 2011-11-24 | Institute For Oneworld Health | Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives |
WO2011133600A1 (en) | 2010-04-20 | 2011-10-27 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine sulfonamide derivatives |
KR101379370B1 (ko) | 2010-04-24 | 2014-03-28 | 비아멧 파마슈티컬즈, 인코포레이티드 | 금속효소 억제제 화합물 |
US20120208855A1 (en) | 2010-07-12 | 2012-08-16 | Sanofi | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
PT2598500T (pt) | 2010-07-28 | 2021-07-22 | Rigel Pharmaceuticals Inc | Composições e métodos para a inibição da via jak |
EP2632903A4 (en) | 2010-10-28 | 2014-11-26 | Viamet Pharmaceuticals Inc | METALLOENZYMHEMMERVERBINDUNGEN |
SI2635299T1 (sl) | 2010-11-02 | 2020-02-28 | The Trustees Of Columbia University In The City Of New York | Postopki za zdravljenje motenj izgube las |
EP2638021B1 (en) | 2010-11-13 | 2018-09-26 | Innocrin Pharmaceuticals, Inc. | 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer |
EP2651905B1 (en) | 2010-12-13 | 2017-07-19 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
EP2654500B1 (en) | 2010-12-20 | 2017-07-19 | Colgate-Palmolive Company | Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier |
EP2678297A2 (en) | 2011-02-25 | 2014-01-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chrysophaentin analogs that inhibit ftsz protein |
KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
EP3398944A1 (en) | 2011-06-19 | 2018-11-07 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
AU2012273161B9 (en) | 2011-06-19 | 2017-07-06 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
IN2014DN00286A (ko) | 2011-06-23 | 2015-06-05 | Viamet Pharmaceuticals Inc | |
WO2013019169A1 (en) | 2011-08-01 | 2013-02-07 | Institute For Oneworld Health | Phosphate prodrugs |
EA033256B1 (ru) | 2011-08-18 | 2019-09-30 | Байоделивери Сайенсиз Интернэшнл, Инк. | Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина |
BR112014005104A2 (pt) | 2011-09-02 | 2017-07-04 | Salk Inst For Biological Studi | inibidores camkii, ip3r, calcineurin, p38 e mk2/3 para tratar atar distúrbios metabólicos de obesidade |
RS57248B1 (sr) | 2011-12-11 | 2018-07-31 | Viamet Pharmaceuticals Nc Inc | Jedinjenja inhibitori metaloenzima |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
IN2014DN06792A (ko) | 2012-01-20 | 2015-05-22 | Viamet Pharmaceuticals Inc | |
AU2013235729B2 (en) | 2012-03-23 | 2017-06-01 | Baylor University | Compositions and methods for inhibition of cathepsins |
DK2830662T3 (da) | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
EP2948150A1 (en) | 2013-01-25 | 2015-12-02 | Rigel Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory bowel diseases |
WO2014151734A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
WO2015089310A1 (en) * | 2013-12-11 | 2015-06-18 | Atkinson Oscar | Occlusive skin covering |
US20150174386A1 (en) * | 2013-12-19 | 2015-06-25 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
JP6625071B2 (ja) | 2014-03-07 | 2019-12-25 | ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性crmp2ペプチド |
CA2942231A1 (en) | 2014-03-19 | 2015-09-24 | Viamet Pharmaceuticals, Inc. | Antifungal compound process |
WO2016105517A1 (en) | 2014-12-23 | 2016-06-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
SI3271347T1 (sl) | 2015-03-19 | 2022-11-30 | Mycovia Pharmaceuticals, Inc. | Protiglivične spojine in postopki za izdelavo |
ES2811136T3 (es) | 2015-08-04 | 2021-03-10 | Rigel Pharmaceuticals Inc | Compuestos de benzazol y métodos para obtener y usar los compuestos |
US10308632B2 (en) | 2015-09-18 | 2019-06-04 | Vps-3, Inc. | Antifungal compounds and processes for making |
US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
KR102240920B1 (ko) | 2015-12-30 | 2021-04-16 | 브이피에스-3, 엘엘씨 | 금속 효소 억제 화합물 |
WO2017155906A1 (en) | 2016-03-08 | 2017-09-14 | Living Proof, Inc. | Long lasting cosmetic compositions |
ES2940911T3 (es) | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
EP3478091B1 (en) | 2016-06-29 | 2024-03-20 | Halo Life Science, LLC | Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline |
US10370367B2 (en) | 2016-10-26 | 2019-08-06 | Rigel Pharmaceuticals, Inc. | IRAK inhibitors and method for making and using |
WO2018081294A1 (en) | 2016-10-26 | 2018-05-03 | Rigel Pharmaceuticals, Inc. | Pyrazole amide compounds as irak inhibitors |
EP3562306B1 (en) | 2016-12-29 | 2025-02-26 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
DK3562487T3 (da) | 2016-12-29 | 2024-01-02 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloenzyminhibitorforbindelser |
GB201708579D0 (en) * | 2017-05-30 | 2017-07-12 | Univ Of Wolverhampton Science Park Ltd | Wound dressing |
EP3645525A1 (en) | 2017-06-29 | 2020-05-06 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
GB2561262B (en) * | 2017-07-13 | 2019-03-20 | Dentmed Ltd | A targeted drug delivery pad |
US10987300B2 (en) | 2017-09-13 | 2021-04-27 | Living Proof, Inc. | Long lasting cosmetic compositions |
US10842729B2 (en) | 2017-09-13 | 2020-11-24 | Living Proof, Inc. | Color protectant compositions |
CN111356501A (zh) | 2017-11-20 | 2020-06-30 | 生活实验公司 | 实现持久化妆品性能的属性 |
US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
AU2019257739B2 (en) | 2018-04-27 | 2025-01-09 | Living Proof, Inc. | Long lasting cosmetic compositions |
SMT202300313T1 (it) | 2018-05-03 | 2024-01-10 | Rigel Pharmaceuticals Inc | Composti inibitori di rip1 e metodi per realizzare e usare gli stessi |
PE20210414A1 (es) | 2018-05-03 | 2021-03-04 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos |
US20220000880A1 (en) | 2018-11-01 | 2022-01-06 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
US11090346B2 (en) | 2019-05-28 | 2021-08-17 | Inbold Inc. | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
CA3147443A1 (en) | 2019-08-08 | 2021-02-11 | Rigel Pharmaceuticals, Inc. | Compounds and method for treating cytokine release syndrome |
EP4013420B1 (en) | 2019-08-14 | 2023-11-01 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
KR20220054626A (ko) | 2019-08-30 | 2022-05-03 | 리겔 파마슈티칼스, 인크. | 피라졸 화합물, 이의 제형, 및 화합물 및/또는 제형을 사용하는 방법 |
JOP20220056A1 (ar) | 2019-09-06 | 2023-01-30 | Rigel Pharmaceuticals Inc | مركبات rip1 تثبيطية وطرق عملها واستخدامها |
BR112022002581A2 (pt) | 2019-09-06 | 2022-07-19 | Rigel Pharmaceuticals Inc | Inibidores heterocíclicos de rip1 quinase |
US11578078B2 (en) | 2019-11-07 | 2023-02-14 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
WO2022187303A1 (en) | 2021-03-03 | 2022-09-09 | Rigel Pharmaceuticals, Inc. | A method for treating a disease or condition using a pyrazole compound or formulation thereof |
TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
WO2023136749A1 (ru) * | 2022-01-11 | 2023-07-20 | Павел Владимирович КОРЧАГИН | Система и способ обеспечения безопасности для держателей банковских карт |
CN119301121A (zh) | 2022-03-23 | 2025-01-10 | 里格尔药品股份有限公司 | 作为irak抑制剂的嘧啶-2-基-吡唑化合物 |
US20230312568A1 (en) | 2022-03-31 | 2023-10-05 | Rigel Pharmaceuticals, Inc. | Tricyclic irak inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
AU1147476A (en) * | 1975-03-19 | 1977-09-01 | Procter & Gamble | Controlled release article |
US4725272A (en) * | 1981-06-29 | 1988-02-16 | Alza Corporation | Novel bandage for administering beneficial drug |
DE3586713T2 (de) * | 1984-11-15 | 1993-05-13 | Hercon Lab | Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen. |
US4752478A (en) * | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
ATE95430T1 (de) * | 1984-12-22 | 1993-10-15 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster. |
US4597961A (en) * | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
GB8512358D0 (en) * | 1985-05-16 | 1985-06-19 | Euro Celtique Sa | Transdermal delivery system |
-
1988
- 1988-02-23 GB GB888804164A patent/GB8804164D0/en active Pending
-
1989
- 1989-02-23 ZA ZA891403A patent/ZA891403B/xx unknown
- 1989-02-23 JP JP1503462A patent/JP2716231B2/ja not_active Expired - Fee Related
- 1989-02-23 WO PCT/GB1989/000185 patent/WO1989007959A1/en active IP Right Grant
- 1989-02-23 US US07/555,463 patent/US5254346A/en not_active Expired - Lifetime
- 1989-02-23 ES ES89903777T patent/ES2052071T3/es not_active Expired - Lifetime
- 1989-02-23 AU AU32895/89A patent/AU618085B2/en not_active Ceased
- 1989-02-23 KR KR1019890701941A patent/KR970009723B1/ko not_active IP Right Cessation
- 1989-02-23 DE DE68915291T patent/DE68915291T2/de not_active Expired - Fee Related
- 1989-02-23 EP EP89903777A patent/EP0508979B1/en not_active Expired - Lifetime
- 1989-02-23 EP EP89301777A patent/EP0336543A1/en active Pending
- 1989-02-23 IN IN173DE1989 patent/IN172748B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU3289589A (en) | 1989-09-22 |
DE68915291T2 (de) | 1994-09-01 |
EP0508979A1 (en) | 1992-10-21 |
JPH03503636A (ja) | 1991-08-15 |
WO1989007959A1 (en) | 1989-09-08 |
ZA891403B (en) | 1989-11-29 |
EP0508979B1 (en) | 1994-05-11 |
JP2716231B2 (ja) | 1998-02-18 |
KR970009723B1 (ko) | 1997-06-17 |
DE68915291D1 (de) | 1994-06-16 |
EP0336543A1 (en) | 1989-10-11 |
IN172748B (ko) | 1993-11-20 |
US5254346A (en) | 1993-10-19 |
ES2052071T3 (es) | 1994-07-01 |
AU618085B2 (en) | 1991-12-12 |
GB8804164D0 (en) | 1988-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900700153A (ko) | 생리학적 활성물질 투여를 위한 폐색체 | |
KR950007808A (ko) | 약물투여용 의료용구 | |
KR910016318A (ko) | 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물 | |
US5071704A (en) | Device for controlled release of vapors and scents | |
KR890701164A (ko) | 피부침투성 치료 시스템 | |
KR930703038A (ko) | 증대된 약제 유량을 나타내는 아포화된 경피적 약제 전달장치 | |
KR900701274A (ko) | 남용 가능성을 감소시킨 용량 제형 | |
KR890011585A (ko) | 경피식 피임약제제형 | |
DE69925936D1 (de) | Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle | |
KR880012216A (ko) | 활성성분 배합물용 경피성 치료계 | |
IE882898L (en) | Solubility modulated drug delivery device | |
EP0922453A3 (en) | Percutaneous absorption type preparation containing tulobuterol | |
DE69121881D1 (de) | Hautelektrodenaufbau und dazugehöriges gerät zur transdermalen verabreichung von heilmitteln | |
KR900005969A (ko) | 게스토덴을 함유하는 경피 투여용 제제 | |
KR910007548A (ko) | 활성성분 플래스터, 그의 제조방법 및 용도 | |
DK0674913T3 (da) | Ikke-okklusivt klæbende plaster til påföring af medicament i huden | |
JPS6485912A (en) | User-activating transdermal treatment system | |
KR850700218A (ko) | 약학 조성물 | |
NO20023135L (no) | <gamma>-IFN v¶skedråpeaerosol og fremgangsmåte for fremstilling av denne | |
SE8300577D0 (sv) | Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad .... | |
CA2010225A1 (en) | Therapeutic System for the Retarded and Controlled Transdermal or Transmucous Administration of Active Substances (1) | |
JPS56100716A (en) | Drug administration member | |
KR100260323B1 (ko) | 약액을구비한일회용밴드 | |
US5558664A (en) | Device for the dermal absorption of medicinal solutes | |
ATE205406T1 (de) | Hauthaftende pharmazeutische zubereitung, insbesondere tts zur abgabe von 17-beta-estradiol an den menschlichen organismus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19891023 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19940221 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19891023 Comment text: Patent Application |
|
G160 | Decision to publish patent application | ||
PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19970522 |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19970912 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19971009 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 19971009 End annual number: 3 Start annual number: 1 |
|
PR1001 | Payment of annual fee |
Payment date: 20000617 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20010702 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20030408 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20031021 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20041001 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20060210 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20070406 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20070406 Start annual number: 10 End annual number: 10 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |